SCHEMBL4247747

SCHEMBL4247747

CCCNc1ncc(C(=O)Nc2cccc(Cl)c2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 1/20 0.53
MAPT P10636 4/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
EPHX1 P07099 3/20 0.49
TP53 P04637 1/20 0.48
MAPK1 P28482 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA9 Q16790 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
GRM4 Q14833 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
POLB P06746 1/20 0.46
KDR P35968 1/20 0.46
ADORA3 P0DMS8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643499 0.97 P4HTM (0.50) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3646879 0.93 EPHX1 (0.53) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL4251689 0.91 P4HTM (0.55) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL4253528 0.89 P4HTM (0.51) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL13930695 0.87 HTT (0.57) MAPTRAB9ASMN1; SMN2NPC1TP53
SCHEMBL3642334 0.84 P4HTM (0.58) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL4255579 0.83 NPC1 (0.55) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3644033 0.83 P4HTM (0.45) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL4257380 0.83 P4HTM (0.60) P4HTMMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3646021 0.82 HTT (0.56) MAPTRAB9ASMN1; SMN2NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US claimed
US-20240307361-A1 METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME Centre for Chinese Herbal Medicine Drug Development Limited (CN) 2024-09-19 US disclosed
US-20240295566-A1 METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS Centre for Chinese Herbal Medicine Drug Development Limited (CN) 2024-09-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240307361-A1 METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME HRH4, VIPR1, TAAR1 P4HTM 2230/4885MAPT 2722/4885RAB9A 861/4885
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS GABBR1, GABBR2, CHRM2 P4HTM 2004/4885MAPT 759/4885RAB9A 733/4885
US-20240295566-A1 METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS TPH1, GPR119, TAAR1 P4HTM 1591/4885MAPT 2343/4885RAB9A 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.